Background: Auckland City Hospital runs a successful nurse-led, with physician overview, elective cardioversion (DCCV) service. DCCV has been proven to be safe and reliable. Novel anticoagulants are now also commonly prescribed for non-valvular AF and DCCV. Methods and Results: An analysis of elective DCCVs between July 2011 and April 2015 and subsequent follow-up was performed. A consecutive 294 patients were identified (79% male; mean: age 59 ± 11, BMI 31 ± 7, CHA2DS2-VASc 1.4, HAS-BLED 0.5, LA area 28cm2; 83% in AF). 57% took dabigatran, 42% warfarin, 1% others. The majority (49% pre-procedurally and 53% post-procedurally) was on beta-blocker mono-therapy. Mean time spent on waiting list were 43 ± 41 days. Successful cardioversion occurred in 92% (mean shock of 1). There was no incidence of MACE or major bleeding. 1 patient (0.3%) had bradycardia and hypotension post DCCV requiring hospitalisation. Mean days to follow-up were 54 ± 54 days. At follow-up, 56% were in SR. Older age was predictive of maintenance of SR (60 vs 57; p=0.023), but not antiarrhythmic agents used (p=0.644). Dabigatran when compared with warfarin was associated with less time spent on waiting list (34 vs 56 days; p<0.005). A lower BMI was predictive of successful DCCV (30kg/m2 vs 33kg/m2; p=0.048). Conclusion: In our cohort, in which a majority of patients was on dabigatran, DCCV remains safe and successful. Time spent on waiting list is significantly reduced with dabigatran. Older age, but not antiarrhythmic agents, predicted maintenance of SR at follow-up.